Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-20 DOI:10.1002/cam4.71235

Chang Jiang, Shengjin Dou, Yu Wang, Wen Jiang, Lulu Ye, Rongrong Li, Xiaolong Fu, Lin Zhang, Guopei Zhu

{"title":"Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck","authors":"Chang Jiang, Shengjin Dou, Yu Wang, Wen Jiang, Lulu Ye, Rongrong Li, Xiaolong Fu, Lin Zhang, Guopei Zhu","doi":"10.1002/cam4.71235","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Amplification of 11q13 (FGF3/4/19, CCND1) is frequently observed in head and neck squamous cell carcinoma (HNSCC). However, there is a lack of research investigating 11q13 amplification as a prognostic marker for patients with locally advanced (LA) HNSCC who undergo postoperative radiotherapy (PORT).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This retrospective study included consecutive patients of LA-HNSCC who underwent radical surgical resection and PORT. The 11q13 amplification was tested by next-generation Sequencing (NGS) or fluorescent in situ hybridization (FISH). Propensity score matching (PSM) was used to match the amplification and wild-type groups. Univariate and multivariate analyses were conducted using Kaplan–Meier and Cox regression. Recurrence patterns and phenotypes in the amplification group were also assessed. Statistical analyses were performed using R software, with a <i>p</i>-value of < 0.05 considered statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 70 patients were included (35 in the 11q13 amplification group and 35 in the wild-type group). Patients with 11q13 amplification exhibited significantly worse disease-free survival (DFS) (3-year DFS: 21.0% vs. 52.6%; <i>p</i> < 0.0019) and overall survival (OS) (3-year OS: 46.4% vs. 66.7%; <i>p</i> = 0.032) compared to wild-type patients. The recurrence pattern in the amplification group showed an approximately equal proportion of local-regional recurrence (LRR) and distant metastases (DM). The LRR predominantly occurred within the 60 Gy radiation field. Multivariate analyses revealed that 11q13 amplification significantly associated with worse DFS (<i>p</i> < 0.001) and OS (<i>p</i> = 0.007).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>LA-HNSCC patients with 11q13 amplification exhibited significantly worse DFS and OS compared to wild-type patients. The recurrence pattern in the 11q13 amplification group was primarily characterized by in-field recurrences within the 60 Gy dose.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 18","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71235","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71235","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Amplification of 11q13 (FGF3/4/19, CCND1) is frequently observed in head and neck squamous cell carcinoma (HNSCC). However, there is a lack of research investigating 11q13 amplification as a prognostic marker for patients with locally advanced (LA) HNSCC who undergo postoperative radiotherapy (PORT).

Materials and Methods

This retrospective study included consecutive patients of LA-HNSCC who underwent radical surgical resection and PORT. The 11q13 amplification was tested by next-generation Sequencing (NGS) or fluorescent in situ hybridization (FISH). Propensity score matching (PSM) was used to match the amplification and wild-type groups. Univariate and multivariate analyses were conducted using Kaplan–Meier and Cox regression. Recurrence patterns and phenotypes in the amplification group were also assessed. Statistical analyses were performed using R software, with a p-value of < 0.05 considered statistically significant.

Results

A total of 70 patients were included (35 in the 11q13 amplification group and 35 in the wild-type group). Patients with 11q13 amplification exhibited significantly worse disease-free survival (DFS) (3-year DFS: 21.0% vs. 52.6%; p < 0.0019) and overall survival (OS) (3-year OS: 46.4% vs. 66.7%; p = 0.032) compared to wild-type patients. The recurrence pattern in the amplification group showed an approximately equal proportion of local-regional recurrence (LRR) and distant metastases (DM). The LRR predominantly occurred within the 60 Gy radiation field. Multivariate analyses revealed that 11q13 amplification significantly associated with worse DFS (p < 0.001) and OS (p = 0.007).

Conclusion

LA-HNSCC patients with 11q13 amplification exhibited significantly worse DFS and OS compared to wild-type patients. The recurrence pattern in the 11q13 amplification group was primarily characterized by in-field recurrences within the 60 Gy dose.

Abstract Image

查看原文本刊更多论文

11q13扩增的头颈部局部晚期鳞状细胞癌的预后和失败模式

背景：11q13 （FGF3/4/19, CCND1）的扩增在头颈部鳞状细胞癌（HNSCC）中经常观察到。然而，缺乏11q13扩增作为局部晚期（LA） HNSCC术后放疗（PORT）患者预后标志物的研究。材料和方法：本回顾性研究包括连续接受根治性手术切除和PORT治疗的LA-HNSCC患者。通过下一代测序（NGS）或荧光原位杂交（FISH）检测11q13扩增。使用倾向评分匹配（PSM）对扩增组和野生型组进行匹配。采用Kaplan-Meier和Cox回归进行单因素和多因素分析。还评估了扩增组的复发模式和表型。采用R软件进行统计学分析，p值为Results：共纳入70例患者，其中11q13扩增组35例，野生型组35例。11q13扩增患者的无病生存期（DFS）明显差(3年DFS: 21.0% vs. 52.6%； p结论：11q13扩增的LA-HNSCC患者的DFS和OS明显差于野生型患者。11q13扩增组的复发模式主要以60 Gy剂量内的场内复发为特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.